Catalyst Pharmaceuticals, Inc. (CPRX)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 15.39 |
| Open | 15.42 |
| Bid | 15.14 x 200 |
| Ask | 15.21 x 100 |
| Day's range | 15.15 - 15.43 |
| 52-week range | 11.55 - 17.50 |
| Volume | |
| Avg. volume | 1,252,272 |
| Market cap | 1.789B |
| Beta (5Y monthly) | 0.73 |
| PE ratio (TTM) | 27.05 |
| EPS (TTM) | 0.56 |
| Earnings date | 26 June 2024 - 30 June 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 27.29 |
ZacksWhy Is Catalyst (CPRX) Up 0.7% Since Last Earnings Report?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Simply Wall St.Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Been Rising: Are Strong Financials Guiding The Market?
Most readers would already know that Catalyst Pharmaceuticals' (NASDAQ:CPRX) stock increased by 4.1% over the past...
GlobeNewswireCatalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its supplemental New Drug Application (“sNDA”) increasing the indicated maximum daily dose of FIRDAPSE® (amifampr
© 2024 Yahoo. All rights reserved.